Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2.
CT-322 is a new anti-angiogenic therapeutic agent based on an engineered variant of the tenth type III domain of human fibronectin, i.e., an Adnectinâ„¢, designed to inhibit vascular endothelial growth factor receptor (VEGFR)-2. This PE Gylated Adnectin was developed using an mRNA display technology. CT-322 bound human VEGFR-2 with high ... affinity (K(D), 11 nM), but did not bind VEGFR-1 or VEGFR-3 at concentrations up to 100 nM, as determined by surface plasmon resonance studies. Western blot analysis showed that CT-322 blocked VEGF-induced phosphorylation of VEGFR-2 and mitogen-activated protein kinase in human umbilical vascular endothelial cells. CT-322 significantly inhibited the growth of human tumor xenograft models of colon carcinoma and glioblastoma at doses of 15-60 mg/kg administered 3 times/week. Anti-tumor effects of CT-322 were comparable to those of sorafenib or sunitinib, which inhibit multiple kinases, in a colon carcinoma xenograft model, although CT-322 caused less overt adverse effects than the kinase inhibitors. CT-322 also enhanced the anti-tumor activity of the chemotherapeutic agent temsirolimus in the colon carcinoma model. The high affinity and specificity of CT-322 binding to VEGFR-2 and its anti-tumor activities establish CT-322 as a promising anti-angiogenic therapeutic agent. Our results further suggest that Adnectins are an important new class of targeted biologics that can be developed as potential treatments for a wide variety of diseases.
Mesh Terms:
Angiogenesis Inhibitors, Animals, Antineoplastic Agents, Carcinoma, Cell Line, Tumor, Colonic Neoplasms, Combinatorial Chemistry Techniques, Endothelium, Vascular, Fibronectins, Glioblastoma, Humans, Mice, Protein Binding, Protein Engineering, Surface Plasmon Resonance, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor-2, Xenograft Model Antitumor Assays
Angiogenesis Inhibitors, Animals, Antineoplastic Agents, Carcinoma, Cell Line, Tumor, Colonic Neoplasms, Combinatorial Chemistry Techniques, Endothelium, Vascular, Fibronectins, Glioblastoma, Humans, Mice, Protein Binding, Protein Engineering, Surface Plasmon Resonance, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor-2, Xenograft Model Antitumor Assays
MAbs
Date: Mar. 02, 2010
PubMed ID: 20190562
View in: Pubmed Google Scholar
Download Curated Data For This Publication
200044
Switch View:
- Interactions 3